These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 9696235

  • 1. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix.
    Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, Van Steirteghem A, Devroey P.
    Fertil Steril; 1998 Aug; 70(2):357-9. PubMed ID: 9696235
    [Abstract] [Full Text] [Related]

  • 2. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
    Tavaniotou A, Albano C, Smitz J, Devroey P.
    Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214
    [Abstract] [Full Text] [Related]

  • 3. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 4. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P.
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [Abstract] [Full Text] [Related]

  • 5. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
    Rongières-Bertrand C, Olivennes F, Righini C, Fanchin R, Taïeb J, Hamamah S, Bouchard P, Frydman R.
    Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
    [Abstract] [Full Text] [Related]

  • 6. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist.
    Tavaniotou A, Albano C, Smitz J, Devroey P.
    Fertil Steril; 2002 Apr; 77(4):733-7. PubMed ID: 11937125
    [Abstract] [Full Text] [Related]

  • 7. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge.
    Leroy I, d'Acremont M, Brailly-Tabard S, Frydman R, de Mouzon J, Bouchard P.
    Fertil Steril; 1994 Sep; 62(3):461-7. PubMed ID: 8062939
    [Abstract] [Full Text] [Related]

  • 8. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM, Nestor JJ, Vickery BH.
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [Abstract] [Full Text] [Related]

  • 9. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
    Ragni G, Vegetti W, Baroni E, Colombo M, Arnoldi M, Lombroso G, Crosignani PG.
    Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
    [Abstract] [Full Text] [Related]

  • 10. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
    Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Van Steirteghem A, Devroey P.
    Fertil Steril; 1997 May; 67(5):917-22. PubMed ID: 9130900
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT, Ohlinger R.
    Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):87-92. PubMed ID: 16377065
    [Abstract] [Full Text] [Related]

  • 12. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles.
    Albano C, Smitz J, Tournaye H, Riethmüller-Winzen H, Van Steirteghem A, Devroey P.
    Hum Reprod; 1999 Jun 01; 14(6):1426-30. PubMed ID: 10357952
    [Abstract] [Full Text] [Related]

  • 13. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles.
    Tavaniotou A, Devroey P.
    Reprod Biomed Online; 2006 Sep 01; 13(3):326-30. PubMed ID: 16984758
    [Abstract] [Full Text] [Related]

  • 14. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J, De Vits A, Joostens M, Van Royen E.
    Hum Reprod; 1995 Jan 01; 10(1):56-62. PubMed ID: 7745071
    [Abstract] [Full Text] [Related]

  • 15. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation.
    Frydman R, Cornel C, de Ziegler D, Taieb J, Spitz IM, Bouchard P.
    Fertil Steril; 1991 Nov 01; 56(5):923-7. PubMed ID: 1936328
    [Abstract] [Full Text] [Related]

  • 16. Activity of gonadotrophin surge-attenuating factor during the luteal phase in superovulated women.
    Messinis IE, MacTavish A, Templeton AA.
    J Reprod Fertil; 1993 Jan 01; 97(1):271-5. PubMed ID: 8464020
    [Abstract] [Full Text] [Related]

  • 17. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol.
    Smitz J, Erard P, Camus M, Devroey P, Tournaye H, Wisanto A, Van Steirteghem AC.
    Hum Reprod; 1992 Oct 01; 7(9):1225-9. PubMed ID: 1479002
    [Abstract] [Full Text] [Related]

  • 18. Administration of a gonadotropin-releasing hormone antagonist to mares at different times during the luteal phase of the estrous cycle.
    Evans MJ, Alexander SL, Irvine CH, Kitson NE, Taylor TB.
    Anim Reprod Sci; 2011 Sep 01; 127(3-4):188-96. PubMed ID: 21889856
    [Abstract] [Full Text] [Related]

  • 19. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L, Tournaye H, Stoop D, Van Vaerenbergh I, Bourgain C, Polyzos NP, Haentjens P, Blockeel C.
    Reprod Biomed Online; 2014 Mar 01; 28(3):359-68. PubMed ID: 24456700
    [Abstract] [Full Text] [Related]

  • 20. The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol.
    Fatemi HM, Camus M, Kolibianakis EM, Tournaye H, Papanikolaou EG, Donoso P, Devroey P.
    Fertil Steril; 2007 Mar 01; 87(3):504-8. PubMed ID: 17140572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.